The stakes could hardly be higher. Cesarean delivery now accounts for roughly 21 percent of births worldwide, a figure projected to climb toward 30 percent by 2030. Poorly managed postoperative pain is not merely a comfort issue; it delays recovery, interferes with newborn care, raises the risk of thromboembolism, and substantially increases rates of chronic postpartum pain and depression. Yet the cesarean population is fundamentally different from the general surgical populations in which the TAP block first proved itself. Most cesarean patients receive neuraxial anesthesia, typically spinal anesthesia, before the incision is made, and that pre-existing analgesic coverage changes the equation in ways that findings from other surgical settings cannot capture. The new review, registered prospectively in PROSPERO and conducted according to PRISMA 2020 guidelines, set out to quantify the block’s effect on postoperative opioid consumption and to determine which clinical variables drive the variability that has plagued the literature.

The researchers systematically searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials from database inception through March 2024, with no language restrictions. Eligible studies enrolled adult patients undergoing cesarean delivery and compared TAP block, performed by any approach and with any local anesthetic formulation, against placebo, no block, or an active comparator such as wound infiltration or quadratus lumborum block. The primary outcome was total opioid consumption within the first 24 hours after surgery, harmonized across different opioid agents using morphine milligram equivalents where necessary. Secondary outcomes included pain scores at rest and on movement at 2, 6, 12, and 24 hours, time to first analgesic request, postoperative nausea and vomiting, adverse effects, patient satisfaction, and quality of recovery. Eighteen studies spanning 2008 to 2024 and enrolling approximately 1,824 patients across four continents made the cut, fourteen of them randomized controlled trials.

Here is where the story takes a statistically dramatic turn. Only four of the eighteen studies provided sufficiently homogeneous numerical data for quantitative pooling, covering just 193 patients. When those four were combined using random-effects modelling with Hedges’ g correction, the pooled estimate showed a statistically significant reduction in 24-hour opioid consumption favoring TAP block, with a standardized mean difference of minus 2.30 and a 95 percent confidence interval of minus 4.24 to minus 0.36, yielding a p-value of 0.02. But the heterogeneity statistic, I-squared, came in at an extraordinary 97 percent, meaning the studies disagreed with each other to a degree that renders any single summary number unreliable. The authors are refreshingly candid about this: the pooled figure, they write, is better understood as a rough average across very different clinical contexts than as a precise summary estimate. The variation itself, they argue, is the more informative result, and it maps directly onto two clinical variables that were pre-specified as subgroup analyses before any data extraction began: the type of anesthesia used and whether intrathecal morphine was part of the regimen.

The general anesthesia subgroup provides the most consistent evidence for TAP block benefit. With no neuraxial analgesia in place, the block addresses anterior abdominal wall somatic pain without competition, and all four studies conducted under general anesthesia reported clinically meaningful opioid-sparing. The numbers are striking. McDonnell and colleagues found cumulative morphine use of 6 milligrams versus 33 milligrams over the first 12 hours, with the median time to first opioid request extended from 90 to 220 minutes. Eslamian’s team reported tramadol requirements reduced from 250 to 75 milligrams and time to first rescue analgesia delayed by more than three hours. Buluc observed that not a single TAP patient required supplemental analgesia beyond the patient-controlled analgesia protocol, compared with 11 of 15 controls. And Tao, in a propensity-matched retrospective cohort, documented a 10-point improvement in the Quality of Recovery-15 scale at 24 hours, exceeding the instrument’s minimum clinically important difference, along with shorter time to ambulation and earlier return of intestinal function. General anesthesia accounts for roughly 5 to 15 percent of cesarean deliveries at many institutions, and considerably more where preservative-free morphine is unavailable or urgent fetal compromise precludes neuraxial placement, making this subgroup far from a niche concern.

The picture reverses when intrathecal morphine enters the equation. Intrathecal morphine remains the reference standard for post-cesarean pain control, providing sustained spinal-level analgesia covering both somatic and visceral components for 12 to 24 hours, though it comes with well-known drawbacks including pruritus, nausea, urinary retention, and the rare but serious risk of delayed respiratory depression. Across the three dedicated studies that examined TAP block as an add-on to intrathecal morphine-based spinal anesthesia, the incremental contribution of the block was negligible. The pooled estimate in this subgroup was a near-zero standardized mean difference of 0.12 with a confidence interval spanning minus 0.34 to 0.58 and a p-value of 0.61. Lee and colleagues saw a real early advantage at 2 hours, with movement pain scores of 1.9 versus 4.9, but it had disappeared entirely by 24 hours. McKeen found no improvement at any time point in 74 patients receiving intrathecal morphine doses of 0.1 to 0.2 milligrams. Singh, comparing high and low doses of ropivacaine against an intrathecal morphine background, found no difference in the primary endpoint at 24 hours. The pharmacology explains it: once intrathecal morphine generates durable opioid receptor-mediated analgesia, a peripheral fascial plane block has very little additional pain left to address.

Spinal anesthesia without intrathecal morphine, whether because morphine is unavailable, opioids are contraindicated, or the institution follows an opioid-minimization protocol, is the other scenario where TAP block reliably contributes. Six of the eight studies in this subgroup showed statistically significant benefit, with magnitudes varying by background analgesic regimen. Jadon’s results were among the most dramatic: the median time to first analgesic request extended from 4 to 11 hours, and median tramadol use dropped from 2 doses to zero. Srivastava recorded a 50 percent reduction in tramadol over 48 hours, and Mankikar more than doubled the rescue-free window from 4.1 to 9.5 hours. Fusco added an important technical observation: when the block was performed correctly under direct ultrasound visualization, far fewer patients crossed the pain threshold of a visual analog scale score of 4 or higher, underscoring that technique quality matters. The two exceptions are instructive rather than contradictory. Yu tested the block against a rigorous scheduled oral regimen of tramadol, celecoxib, and paracetamol with on-demand oxycodone and found it added nothing, demonstrating what structured multimodal analgesia can achieve on its own. Sripriya found that neither posterior TAP nor transversalis fascia plane block reduced total rescue analgesic doses, yet TAP meaningfully extended the pain-free interval from 4.76 to 6.89 hours.

The active comparator data yield two practical conclusions. TAP block and wound infiltration perform essentially the same when local anesthetic volume and concentration are matched, suggesting that delivery route matters less than the total local anesthetic deposited in the abdominal wall, a finding with real implications when operating room time is short. The quadratus lumborum block appears modestly superior at select time points, plausibly because its posterior spread can reach the paravertebral space and capture visceral afferents that TAP cannot, though that advantage is small and the technique is more demanding. Notably, no trial has yet compared the two techniques in an intrathecal morphine-inclusive setting. Even the extended-duration story is underwhelming: Peebles examined liposomal bupivacaine TAP block against liposomal bupivacaine wound infiltration in a retrospective cohort of 402 patients and found both active arms indistinguishable from each other, with the extended-duration agent not changing which technique came out ahead. Secondary outcomes tracked the primary signal: pain benefit typically attenuated or disappeared by 24 hours, in keeping with the 8 to 16 hour functional duration of conventional bupivacaine and ropivacaine, and reduced nausea and vomiting rates in the general anesthesia subgroup reflected predictable downstream effects of lower systemic opioid exposure. One serious adverse event occurred across the entire dataset, a case of systemic local anesthetic toxicity with convulsions that resolved with intravenous midazolam and left no long-term sequelae.

The authors are careful to frame their conclusions as context-dependent and hypothesis-generating rather than definitive clinical prescriptions. The quantitative evidence rests on only four pooled studies, the two observational cohorts carry the usual risk of unmeasured confounding, background analgesic regimens varied widely, and nearly every study reported only short-term outcomes, with Singh’s 6- and 12-week data the lone exception showing no difference at either time point. Still, the clinical message is neither to abandon the block broadly nor to apply it universally, but to use it where the evidence is strongest. Under general anesthesia, TAP block should be strongly considered as a component of postoperative analgesia. When intrathecal morphine is part of the spinal technique, the available evidence does not support routine use, and resources are better directed toward dose optimization and side-effect management. In patients receiving spinal anesthesia without intrathecal morphine, the block appears to provide clinically meaningful analgesia, with the caveat that benefit is attenuated when structured oral analgesia is already reliably implemented. Future trials, the authors argue, should adopt standardized outcome reporting anchored to the IMMPACT core set, mandate intrathecal morphine use as a pre-specified stratification variable, and finally test continuous catheter-based TAP infusion over single-shot blocks in the general anesthesia setting, where the block’s contribution is clearest and duration matters most. Confirmation in adequately powered prospective trials is required before this framework can serve as the basis for formal clinical guidance, but for now, the era of one-size-fits-all TAP blocking after cesarean delivery may be drawing to a close.

Subject of Research: Medicine

Article Title: Is transversus abdominis plane block universally effective after cesarean delivery? A systematic review and meta-analysis

Article References: Riveros-Perez, E., & Avella-Molano, B. (2026). Is transversus abdominis plane block universally effective after cesarean delivery? A systematic review and meta-analysis. Frontiers in Anesthesiology, 5, Article 1861059. https://doi.org/10.3389/fanes.2026.1861059

Image Credits: AI Generated

DOI: 10.3389/fanes.2026.1861059

Keywords: TAP block, cesarean delivery, intrathecal morphine, meta-analysis, regional anesthesia, postoperative pain, opioid-sparing, obstetric anesthesia, transversus, abdominis, plane, block